Vieyra-Garcia Pablo A, Wei Tianling, Naym David Gram, Fredholm Simon, Fink-Puches Regina, Cerroni Lorenzo, Odum Niels, O'Malley John T, Gniadecki Robert, Wolf Peter
Research Unit for Photodermatology, Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.
Department of Dermatology, Bispebjerg Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
Clin Cancer Res. 2016 Jul 1;22(13):3328-39. doi: 10.1158/1078-0432.CCR-15-1784. Epub 2016 Feb 5.
Sustained inflammation is a key feature of mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL). Resident IL9-producing T cells have been found in skin infections and certain inflammatory skin diseases, but their role in MF is currently unknown.
We analyzed lesional skin from patients with MF for the expression of IL9 and its regulators. To determine which cells were producing IL9, high-throughput sequencing was used to identify malignant clones and Vb-specific antibodies were employed to visualize malignant cells in histologic preparations. To explore the mechanism of IL9 secretion, we knocked down STAT3/5 and IRF4 by siRNA transfection in CTCL cell lines receiving psoralen+UVA (PUVA) ± anti-IL9 antibody. To further examine the role of IL9 in tumor development, the EL-4 T-cell lymphoma model was used in C57BL/6 mice.
Malignant and reactive T cells produce IL9 in lesional skin. Expression of the Th9 transcription factor IRF4 in malignant cells was heterogeneous, whereas reactive T cells expressed it uniformly. PUVA or UVB phototherapy diminished the frequencies of IL9- and IL9r-positive cells, as well as STAT3/5a and IRF4 expression in lesional skin. IL9 production was regulated by STAT3/5 and silencing of STAT5 or blockade of IL9 with neutralizing antibodies potentiated cell death after PUVA treatment in vitro IL9-depleted mice exhibited a reduction of tumor growth, higher frequencies of regulatory T cells, and activated CD4 and CD8 T lymphocytes.
Our results suggest that IL9 and its regulators are promising new targets for therapy development in mycosis fungoides. Clin Cancer Res; 22(13); 3328-39. ©2016 AACR.
持续性炎症是蕈样肉芽肿(MF)的关键特征,MF是皮肤T细胞淋巴瘤(CTCL)最常见的形式。在皮肤感染和某些炎症性皮肤病中已发现产生白细胞介素9(IL9)的常驻T细胞,但其在MF中的作用目前尚不清楚。
我们分析了MF患者的皮损组织中IL9及其调节因子的表达情况。为确定产生IL9的细胞类型,采用高通量测序来鉴定恶性克隆,并使用Vβ特异性抗体在组织学标本中可视化恶性细胞。为探究IL9分泌的机制,我们在接受补骨脂素+紫外线A(PUVA)±抗IL9抗体处理的CTCL细胞系中,通过小干扰RNA(siRNA)转染敲低信号转导和转录激活因子3/5(STAT3/5)和干扰素调节因子4(IRF4)。为进一步研究IL9在肿瘤发生中的作用,在C57BL/6小鼠中使用EL-4 T细胞淋巴瘤模型。
恶性和反应性T细胞在皮损组织中产生IL9。恶性细胞中Th9转录因子IRF4的表达是异质性的,而反应性T细胞则均匀表达。PUVA或紫外线B(UVB)光疗可降低皮损组织中IL9和IL9受体阳性细胞的频率,以及STAT3/5a和IRF4的表达。IL9的产生受STAT3/5调节,在体外,沉默STAT5或用中和抗体阻断IL9可增强PUVA处理后的细胞死亡。IL9缺失的小鼠肿瘤生长减缓,调节性T细胞频率增加,CD4和CD8 T淋巴细胞活化。
我们的结果表明,IL9及其调节因子是蕈样肉芽肿治疗开发中很有前景的新靶点。《临床癌症研究》;22(13);3328 - 3339。©2016美国癌症研究协会。